Personalized approach to antipsychotic-induced weight gain prognosis

Vera S Dobrodeeva,Regina F Nasyrova,Aiperi K Abdyrahmanova

doi:10.52667/2712-9179-2021-1-1-3-10

Vera S Dobrodeeva, Regina F Nasyrova + Show 1 more

Open Access

https://doi.org/10.52667/2712-9179-2021-1-1-3-10

Copy DOI

Journal: Personalized Psychiatry and Neurology	Publication Date: Jan 1, 2021
Citations: 6	License type: cc-by

Abstract

Abstract: Antipsychotics (APs) are the base of schizophrenia pharmacotherapy. There are large individual differences in effectiveness and adverse drug reactions (ADRs) of APs. There is an urgent need for a personalized approach to the therapy. Genetic factors are predisposed to patient's response to APs therapy. Pharmacogenetic studies of APs have examined a number of single nucleotide variants (SNVs), of which only a few were associated with therapeutic efficacy and ADRs development. However, only a limited number of these results have clinical applications in psychiatry. Nowadays, it seems promising to study SNVs of leptin system genes (LEP, LEPR) and neuropeptide Y (NRY). Studying the mechanisms of APs-induced weight growth will allow their transmission to a personalized approach. It will help psychiatrists in patients’ selection for the APs therapy. This will increase safety and effectiveness of the therapy, improve the quality of life and adherence to therapy in patients with schizophrenia.

Highlights

Аntipsychotics (APs) are the drugs of choice for schizophrenic spectrum disorders treatment
Weight increase while taking APs is an important factor in development of obesity in patients with schizophrenia
According to the World Health Organization (WHO) definition, obesity is characterized by excessive accumulation of adipose tissue in a body and is measured by such an indicator as body mass index (BMI)

Summary

Introduction

Аntipsychotics (APs) are the drugs of choice for schizophrenic spectrum disorders treatment. Weight increase while taking APs is an important factor in development of obesity in patients with schizophrenia. Stimulation of appetite and inhibition of satiety can provoke development of dyslipidemia and cause body weight increase in patients receiving atypical APs. Genes encoding leptin (LEP), leptin receptor (LEPR), and neuropeptide Y (NPY) appear to be promising candidate genes for studying APs-induced weight gain.

Results

Conclusion